iBio licenses anti-myostatin antibody IBIO-600 from AstralBio; launches bispecific program for obesity

iBio, Inc.

Upfront payment of $750,000 paid in common stock; milestones up to $28M.
IBIO-600 is a long-acting anti-myostatin antibody designed for subcutaneous use.
iBio initiated a bispecific antibody program targeting myostatin/activin A for obesity and cardiometabolic disorders.
Preclinical studies show potent myostatin inhibition; NHP data expected early 2025.
Plans to enter clinical trials in obesity and cardiometabolic disorders in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.